Drug Type CAR-T |
Synonyms Anti-CD22 CAR-T cell therapy (IASO Biotherapeutics), RD 102, RD102 |
Target |
Action inhibitors |
Mechanism CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Diffuse Large B-Cell Lymphoma | Phase 1 | China | 15 Aug 2019 | |
| Acute Lymphoblastic Leukemia | Phase 1 | China | 04 Aug 2019 |





